Consolidated Statements of Cash Flows (unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	$ (2,107)	$ (2,685)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on sale of subsidiaries, net of adjustments	0	150
Depreciation and amortization	293	360
Amortization of deferred financing fees	83	83
Provision for bad debt expense	6	(30)
Share-based compensation expense	89	77
Change in assets and liabilities:
Accounts receivable	(1,697)	(672)
Inventories	201	(81)
Other assets	(38)	(229)
Accounts payable, accrued expenses and other liabilities	(431)	1,292
Net cash used in operating activities	(3,601)	(1,735)
Cash flows from investing activities:
Capital expenditures	(213)	(327)
Proceeds from the sale of Portamedic	0	743
Net cash (used in) provided by investing activities	(213)	416
Cash flows from financing activities:
Payments on capital lease obligations	0	(1)
Proceeds related to the exercise of stock options	0	17
Net cash provided by financing activities	0	16
Net decrease in cash and cash equivalents	(3,814)	(1,303)
Cash and cash equivalents at beginning of period	5,201	3,970
Cash and cash equivalents at end of period	1,387	2,667
Supplemental disclosure of non-cash investing activities:
Fixed assets vouchered but not paid	76	230
Supplemental disclosure of cash paid during period for:
Income taxes	$ 0	$ 0